Not available in the U.S.

Melperone

BURONIL

Open Melperone in the interactive console ↗

Melperone ballicule: receptor binding, kinetics and half-life diagram — Mechanism of action: Melperone ballicule

What it isMelperone (BURONIL): atypical butyrophenone antipsychotic approved in several European countries, never FDA-approved. Low-EPS profile; used for agitation and psychosis, mostly in older adults. Short half-life (~4 h); clinically relevant CYP2D6 inhibition (TDM: dose-corrected venlafaxine ≈+72%).

Why this oneModerate-to-low-affinity D2 and 5-HT2A antagonism with alpha-1 and H1 blockade — an atypical profile despite its first-generation butyrophenone chemistry.

What limits itNever FDA-approved (ruling 5: shown as N/A); dose-dependent QT prolongation reported in the class — treat like other low-potency antipsychotics for monitoring.

Melperone molecular structure (skeletal formula) — Molecular structure: Melperone

FDA-approved for

schizophrenia / agitation (non-US)

⚠ BOXED WARNING

Increased mortality in elderly patients with dementia-related psychosis

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4

Overdose danger3 / 4

Weight-gain liability0 / 4

Sedation liability3 / 4

QT / Torsades1 / 4

Direct muscarinic antagonism0 / 4

Defining liabilitySedation, orthostasis and ventricular arrhythmia risk

Open Melperone in the interactive console ↗

Self-check

Is melperone FDA-approved?
No.
Which CYP enzyme does melperone inhibit clinically?
CYP2D6.